- Home
- GLDG vs ME Comparison
GLDG vs ME Comparison
Compare GLDG & ME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLDG
- ME
- Stock Information
- Founded
- GLDG 2009
- ME 2006
- Country
- GLDG Canada
- ME United States
- Employees
- GLDG N/A
- ME N/A
- Industry
- GLDG Precious Metals
- ME Precision Instruments
- Sector
- GLDG Basic Materials
- ME Health Care
- Exchange
- GLDG Nasdaq
- ME Nasdaq
- Market Cap
- GLDG 173.2M
- ME 168.9M
- IPO Year
- GLDG N/A
- ME N/A
- Fundamental
- Price
- GLDG $1.01
- ME $0.34
- Analyst Decision
- GLDG Strong Buy
- ME Hold
- Analyst Count
- GLDG 1
- ME 1
- Target Price
- GLDG $5.25
- ME $0.47
- AVG Volume (30 Days)
- GLDG 1.0M
- ME 2.4M
- Earning Date
- GLDG 10-11-2024
- ME 11-06-2024
- Dividend Yield
- GLDG N/A
- ME N/A
- EPS Growth
- GLDG N/A
- ME N/A
- EPS
- GLDG N/A
- ME N/A
- Revenue
- GLDG N/A
- ME $199,188,000.00
- Revenue This Year
- GLDG N/A
- ME $0.05
- Revenue Next Year
- GLDG N/A
- ME $17.98
- P/E Ratio
- GLDG N/A
- ME N/A
- Revenue Growth
- GLDG N/A
- ME N/A
- 52 Week Low
- GLDG $0.75
- ME $0.29
- 52 Week High
- GLDG $1.08
- ME $1.09
- Technical
- Relative Strength Index (RSI)
- GLDG 65.39
- ME 49.74
- Support Level
- GLDG $0.98
- ME $0.29
- Resistance Level
- GLDG $1.06
- ME $0.36
- Average True Range (ATR)
- GLDG 0.05
- ME 0.02
- MACD
- GLDG 0.01
- ME 0.01
- Stochastic Oscillator
- GLDG 76.09
- ME 64.86
About GLDG GoldMining Inc.
GoldMining Inc is a mineral exploration company with a focus on the acquisition, exploration, and development of projects in Colombia, Brazil, the United States, Canada, and Peru. The principal projects are its La Mina Gold project and its Titiribi Gold-Copper project, located in Colombia, Crucero project, located in Peru, Sao Jorge, Batistao, Boa Vista, located in Brazil, Yellowknife Gold Project, located in the Northwest Territories, Canada, and other projects. The company earns maximum revenue from Canada.
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.